ANSBERT GADICKE Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for ANSBERT GADICKE.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of ANSBERT GADICKE. ANSBERT GADICKE is 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and Director in CHIASMA, INC ($CHMA) and Director in Radius Health, Inc. ($RDUS) and 10% Owner in Harpoon Therapeutics, Inc. ($HARP) and Director in Allovir, Inc. ($ALVR) and Director in TCR2 THERAPEUTICS INC. ($TCRR) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in iTeos Therapeutics, Inc. ($ITOS) and Director in iTeos Therapeutics, Inc. ($ITOS) and 10% Owner in Repare Therapeutics Inc. ($RPTX) and Director in Cullinan Management, Inc. ($CGEM).
Latest Insider Trading Transactions of ANSBERT GADICKE
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ALVR, CHMA, CGEM, HARP, ITOS, RDUS, RPTX, RIGL, TCRR, HOWL
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 02 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | S | 32.42 | 297 | 9,629 | 4,202,574 | 4.2 M to 4.2 M (-0.01 %) |
| Jun 02 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | S | 31.83 | 5,918 | 188,370 | 4,202,871 | 4.2 M to 4.2 M (-0.14 %) |
| Jun 02 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | S | 32.50 | 15,141 | 492,083 | 4,208,789 | 4.2 M to 4.2 M (-0.36 %) |
| Jun 02 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | S | 32.67 | 16,742 | 546,961 | 4,223,930 | 4.2 M to 4.2 M (-0.39 %) |
| May 24 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | S | 34.28 | 18,653 | 639,425 | 4,279,231 | 4.3 M to 4.3 M (-0.43 %) |
| May 24 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | S | 33.30 | 3,547 | 118,115 | 4,297,884 | 4.3 M to 4.3 M (-0.08 %) |
| May 24 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | S | 34.80 | 302,669 | 10,532,881 | 4,301,431 | 4.6 M to 4.3 M (-6.57 %) |
| May 24 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 20.12 | 5,000 | 100,600 | 6,402,748 | 6.4 M to 6.4 M (-0.08 %) |
| May 24 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 20.21 | 10,907 | 220,430 | 6,407,748 | 6.4 M to 6.4 M (-0.17 %) |
| May 20 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | S | 35.19 | 600 | 21,114 | 4,604,100 | 4.6 M to 4.6 M (-0.01 %) |
| May 20 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | S | 34.66 | 9,357 | 324,314 | 4,604,700 | 4.6 M to 4.6 M (-0.20 %) |
| May 20 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | S | 35.00 | 4,400 | 154,000 | 4,614,057 | 4.6 M to 4.6 M (-0.10 %) |
| May 20 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | S | 34.23 | 9,143 | 312,965 | 4,618,457 | 4.6 M to 4.6 M (-0.20 %) |
| May 20 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | J | 0.00 | 21,834 | 0 | 4,627,600 | 4.6 M to 4.6 M (-0.47 %) |
| May 20 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | S | 35.14 | 90 | 3,163 | 4,649,434 | 4.6 M to 4.6 M (0.00 %) |
| May 20 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | S | 34.61 | 8,541 | 295,604 | 4,649,524 | 4.7 M to 4.6 M (-0.18 %) |
| May 20 2021 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Sell | S | 33.90 | 14,773 | 500,805 | 4,658,065 | 4.7 M to 4.7 M (-0.32 %) |
| May 12 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 20.53 | 29,684 | 609,413 | 6,483,024 | 6.5 M to 6.5 M (-0.46 %) |
| May 12 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 21.51 | 7,672 | 165,025 | 6,512,708 | 6.5 M to 6.5 M (-0.12 %) |
| May 12 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 20.96 | 13,773 | 288,682 | 6,520,380 | 6.5 M to 6.5 M (-0.21 %) |
| May 12 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 22.46 | 411 | 9,231 | 6,534,153 | 6.5 M to 6.5 M (-0.01 %) |
| May 12 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 21.78 | 16,722 | 364,205 | 6,534,564 | 6.6 M to 6.5 M (-0.26 %) |
| May 06 2021 | HOWL | Werewolf Therapeut ... | GADICKE ANSBERT | 10% Owner | Option Exercise | C | 0.00 | 12,899,925 | 0 | 0 | |
| May 06 2021 | HOWL | Werewolf Therapeut ... | GADICKE ANSBERT | 10% Owner | Option Exercise | C | 0.00 | 38,817,998 | 0 | 0 | |
| May 06 2021 | HOWL | Werewolf Therapeut ... | GADICKE ANSBERT | 10% Owner | Buy | P | 16.00 | 245,000 | 3,920,000 | 6,672,183 | 6.4 M to 6.7 M (+3.81 %) |
| May 06 2021 | HOWL | Werewolf Therapeut ... | GADICKE ANSBERT | 10% Owner | Buy | C | 0.00 | 1,488,033 | 0 | 6,427,183 | 4.9 M to 6.4 M (+30.13 %) |
| May 06 2021 | HOWL | Werewolf Therapeut ... | GADICKE ANSBERT | 10% Owner | Buy | C | 0.00 | 4,477,742 | 0 | 4,939,150 | 461.4 K to 4.9 M (+970.45 %) |
| May 04 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 23.33 | 3,500 | 81,655 | 6,561,458 | 6.6 M to 6.6 M (-0.05 %) |
| May 04 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 23.03 | 26,230 | 604,077 | 6,564,958 | 6.6 M to 6.6 M (-0.40 %) |
| May 04 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 23.45 | 4,401 | 103,203 | 6,591,188 | 6.6 M to 6.6 M (-0.07 %) |
| May 04 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 23.03 | 26,365 | 607,186 | 6,595,589 | 6.6 M to 6.6 M (-0.40 %) |
| May 04 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 22.35 | 268,023 | 5,990,314 | 6,621,954 | 6.9 M to 6.6 M (-3.89 %) |
| Apr 29 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 22.54 | 21,781 | 490,944 | 6,889,977 | 6.9 M to 6.9 M (-0.32 %) |
| Apr 29 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 22.02 | 45,511 | 1,002,152 | 6,911,758 | 7 M to 6.9 M (-0.65 %) |
| Apr 29 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 22.01 | 36,803 | 810,034 | 6,957,269 | 7 M to 7 M (-0.53 %) |
| Apr 29 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 21.64 | 14,219 | 307,699 | 6,994,072 | 7 M to 7 M (-0.20 %) |
| Apr 29 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 21.26 | 8,328 | 177,053 | 7,008,291 | 7 M to 7 M (-0.12 %) |
| Apr 29 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 20.99 | 3,501 | 73,486 | 7,016,619 | 7 M to 7 M (-0.05 %) |
| Apr 20 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 19.09 | 834 | 15,921 | 7,029,092 | 7 M to 7 M (-0.01 %) |
| Apr 20 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 18.70 | 21,415 | 400,461 | 7,029,926 | 7.1 M to 7 M (-0.30 %) |
| Apr 20 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 20.08 | 100 | 2,008 | 7,051,341 | 7.1 M to 7.1 M (0.00 %) |
| Apr 20 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 19.29 | 9,956 | 192,051 | 7,051,441 | 7.1 M to 7.1 M (-0.14 %) |
| Apr 20 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 20.56 | 300 | 6,168 | 7,061,397 | 7.1 M to 7.1 M (0.00 %) |
| Apr 20 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 19.82 | 5,547 | 109,942 | 7,061,697 | 7.1 M to 7.1 M (-0.08 %) |
| Apr 15 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 20.49 | 8,696 | 178,181 | 7,067,244 | 7.1 M to 7.1 M (-0.12 %) |
| Apr 15 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 20.83 | 12,806 | 266,749 | 7,075,940 | 7.1 M to 7.1 M (-0.18 %) |
| Apr 15 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 20.06 | 1,000 | 20,060 | 7,088,746 | 7.1 M to 7.1 M (-0.01 %) |
| Apr 15 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 20.08 | 2,362 | 47,429 | 7,089,746 | 7.1 M to 7.1 M (-0.03 %) |
| Apr 15 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 19.35 | 13,692 | 264,940 | 7,092,108 | 7.1 M to 7.1 M (-0.19 %) |
| Apr 13 2021 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | 10% Owner | Sell | S | 29.99 | 200 | 5,998 | 6,004,368 | 6 M to 6 M (0.00 %) |
| Apr 13 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 22.68 | 400 | 9,072 | 7,105,800 | 7.1 M to 7.1 M (-0.01 %) |
| Apr 13 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 21.52 | 6,700 | 144,184 | 7,106,200 | 7.1 M to 7.1 M (-0.09 %) |
| Apr 13 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 20.72 | 13,528 | 280,300 | 7,112,900 | 7.1 M to 7.1 M (-0.19 %) |
| Apr 13 2021 | HARP | Harpoon Therapeuti ... | GADICKE ANSBERT | 10% Owner | Sell | S | 23.67 | 10,300 | 243,801 | 7,126,428 | 7.1 M to 7.1 M (-0.14 %) |
| Apr 09 2021 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | 10% Owner | Sell | S | 31.01 | 414 | 12,838 | 6,004,568 | 6 M to 6 M (-0.01 %) |
| Apr 09 2021 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | 10% Owner | Sell | S | 30.51 | 31,890 | 972,964 | 6,004,982 | 6 M to 6 M (-0.53 %) |
| Apr 09 2021 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | 10% Owner | Sell | S | 31.01 | 414 | 12,838 | 6,004,568 | 6 M to 6 M (-0.01 %) |
| Apr 09 2021 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | 10% Owner | Sell | J | 0.00 | 15,670 | 0 | 6,036,872 | 6.1 M to 6 M (-0.26 %) |
| Apr 09 2021 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | 10% Owner | Sell | S | 30.51 | 31,890 | 972,964 | 6,004,982 | 6 M to 6 M (-0.53 %) |
| Apr 09 2021 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | 10% Owner | Sell | S | 33.84 | 1,300 | 43,992 | 6,052,542 | 6.1 M to 6.1 M (-0.02 %) |
| Apr 09 2021 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | 10% Owner | Sell | J | 0.00 | 15,670 | 0 | 6,036,872 | 6.1 M to 6 M (-0.26 %) |
| Apr 09 2021 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | 10% Owner | Sell | S | 32.84 | 3,083 | 101,246 | 6,053,842 | 6.1 M to 6.1 M (-0.05 %) |
| Apr 09 2021 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | 10% Owner | Sell | S | 33.84 | 1,300 | 43,992 | 6,052,542 | 6.1 M to 6.1 M (-0.02 %) |
| Apr 09 2021 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | 10% Owner | Sell | S | 32.07 | 5,295 | 169,811 | 6,056,925 | 6.1 M to 6.1 M (-0.09 %) |
| Apr 09 2021 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | 10% Owner | Sell | S | 32.84 | 3,083 | 101,246 | 6,053,842 | 6.1 M to 6.1 M (-0.05 %) |
| Apr 09 2021 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | 10% Owner | Sell | S | 32.07 | 5,295 | 169,811 | 6,056,925 | 6.1 M to 6.1 M (-0.09 %) |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 649,030 | 0 | 0 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 2,276,692 | 0 | 0 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 3,551,640 | 0 | 0 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 1,136,525 | 0 | 0 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Option Exercise | J | 4.30 | 88,824 | 381,943 | 88,824 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Option Exercise | J | 4.30 | 262,114 | 1,127,090 | 262,114 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Option Exercise | J | 0.00 | 649,030 | 0 | 649,030 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Option Exercise | J | 0.00 | 2,276,692 | 0 | 2,276,692 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Option Exercise | J | 0.00 | 3,551,640 | 0 | 3,551,640 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Option Exercise | J | 0.00 | 1,136,525 | 0 | 1,136,525 | |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Buy | P | 21.00 | 300,000 | 6,300,000 | 7,913,887 | 7.6 M to 7.9 M (+3.94 %) |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 649,030 | 0 | 7,613,887 | 7 M to 7.6 M (+9.32 %) |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 2,276,692 | 0 | 6,964,857 | 4.7 M to 7 M (+48.56 %) |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 3,551,640 | 0 | 4,688,165 | 1.1 M to 4.7 M (+312.50 %) |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 1,136,525 | 0 | 1,136,525 | 0 to 1.1 M |
| Jan 14 2021 | CGEM | Cullinan Managemen ... | GADICKE ANSBERT | Director | Buy | J | 0.00 | 281,268 | 0 | 281,268 | 0 to 281.3 K |
| Aug 05 2020 | ALVR | Allovir, Inc. | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 20,000,000 | 0 | 0 | |
| Aug 05 2020 | ALVR | Allovir, Inc. | GADICKE ANSBERT | Director | Buy | C | 0.00 | 13,420,970 | 0 | 13,420,970 | 0 to 13.4 M |
| Jul 31 2020 | ALVR | Allovir, Inc. | GADICKE ANSBERT | Director | Option Exercise | A | 17.00 | 22,500 | 382,500 | 22,500 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 2,600,628 | 0 | 0 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 29,440 | 0 | 0 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 79,281 | 0 | 0 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 1,491,666 | 0 | 0 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 81,295 | 0 | 0 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 157,529 | 0 | 0 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 2,361,805 | 0 | 0 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 4,211,330 | 0 | 0 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 47,674 | 0 | 0 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 128,384 | 0 | 0 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 2,415,530 | 0 | 0 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 131,645 | 0 | 0 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 255,094 | 0 | 0 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 3,824,591 | 0 | 0 | |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | P | 19.00 | 160,000 | 3,040,000 | 2,355,557 | 2.2 M to 2.4 M (+7.29 %) |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | P | 19.00 | 1,121 | 21,299 | 25,974 | 24.9 K to 26 K (+4.51 %) |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | P | 19.00 | 3,020 | 57,380 | 69,951 | 66.9 K to 70 K (+4.51 %) |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | P | 19.00 | 56,814 | 1,079,466 | 1,316,139 | 1.3 M to 1.3 M (+4.51 %) |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | P | 19.00 | 3,096 | 58,824 | 71,727 | 68.6 K to 71.7 K (+4.51 %) |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | P | 19.00 | 5,994 | 113,886 | 138,985 | 133 K to 139 K (+4.51 %) |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | P | 19.00 | 89,955 | 1,709,145 | 2,083,887 | 2 M to 2.1 M (+4.51 %) |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 797,983 | 0 | 2,195,557 | 1.4 M to 2.2 M (+57.10 %) |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 9,033 | 0 | 24,853 | 15.8 K to 24.9 K (+57.10 %) |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 24,326 | 0 | 66,931 | 42.6 K to 66.9 K (+57.10 %) |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 457,706 | 0 | 1,259,325 | 801.6 K to 1.3 M (+57.10 %) |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 24,944 | 0 | 68,381 | 43.4 K to 68.4 K (+57.43 %) |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 48,336 | 0 | 132,991 | 84.7 K to 133 K (+57.10 %) |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 724,702 | 0 | 1,993,932 | 1.3 M to 2 M (+57.10 %) |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 1,397,574 | 0 | 1,397,574 | 0 to 1.4 M |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 15,820 | 0 | 15,820 | 0 to 15.8 K |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 42,605 | 0 | 42,605 | 0 to 42.6 K |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 801,619 | 0 | 801,619 | 0 to 801.6 K |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 43,687 | 0 | 43,687 | 0 to 43.7 K |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 84,655 | 0 | 84,655 | 0 to 84.7 K |
| Jul 30 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 1,269,230 | 0 | 1,269,230 | 0 to 1.3 M |
| Jul 24 2020 | ITOS | iTeos Therapeutics ... | GADICKE ANSBERT | Director | Option Exercise | A | 19.00 | 16,608 | 315,552 | 0 | |
| Jun 25 2020 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Option Exercise | C | 0.00 | 1,288,948 | 0 | 0 | |
| Jun 25 2020 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Option Exercise | C | 0.00 | 3,603,161 | 0 | 0 | |
| Jun 25 2020 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Buy | P | 20.00 | 500,000 | 10,000,000 | 5,392,109 | 4.9 M to 5.4 M (+10.22 %) |
| Jun 25 2020 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Buy | C | 0.00 | 1,288,948 | 0 | 4,892,109 | 3.6 M to 4.9 M (+35.77 %) |
| Jun 25 2020 | RPTX | Repare Therapeutic ... | GADICKE ANSBERT | 10% Owner | Buy | C | 0.00 | 3,603,161 | 0 | 3,603,161 | 0 to 3.6 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 1,750,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 217,500 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 1,586,623 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 105,825 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 32,500 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 57,552 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 15,000,000 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 2,174,998 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 13,599,621 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 907,073 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 325,002 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Option Exercise | C | 0.00 | 493,306 | 0 | 0 | |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | P | 15.00 | 1,373,333 | 20,599,995 | 1,569,235 | 195.9 K to 1.6 M (+701.03 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 282,540 | 0 | 2,704,315 | 2.4 M to 2.7 M (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 35,115 | 0 | 386,270 | 351.2 K to 386.3 K (+10.00 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 256,163 | 0 | 2,451,844 | 2.2 M to 2.5 M (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 17,085 | 0 | 163,532 | 146.4 K to 163.5 K (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 5,247 | 0 | 57,716 | 52.5 K to 57.7 K (+10.00 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 9,291 | 0 | 88,935 | 79.6 K to 88.9 K (+11.67 %) |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 2,421,775 | 0 | 2,421,775 | 0 to 2.4 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 351,155 | 0 | 351,155 | 0 to 351.2 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 2,195,681 | 0 | 2,195,681 | 0 to 2.2 M |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 146,447 | 0 | 146,447 | 0 to 146.4 K |
| Feb 21 2019 | TCRR | TCR2 THERAPEUTICS ... | GADICKE ANSBERT | Director | Buy | C | 0.00 | 52,469 | 0 | 52,469 | 0 to 52.5 K |